@article {Guenther:December 2006:1746-9872:791,
	author = "Guenther, Lyn C",
	title = "Calcipotriene/betamethasone dipropionate: a new topical ointment for psoriasis",
	journal = "Expert Review of Dermatology",
	volume = "1",
	year = "December 2006",
	abstract = "Topical steroids and calcipotriene are the mainstay of treatment for mild-to-moderate psoriasis. They are used as monotherapy or in combination in an a.m./p.m. regimen owing to drug incompatibility. Recently, the US FDA approved a once-daily stable two-compound ointment containing calcipotriene and betamethasone dipropionate (Taclonex<SUP>&#174;</SUP>). This product has been marketed in other countries under the names Dovobet<SUP>&#174;</SUP> and Daivobet<SUP>&#174;</SUP>. It is convenient with a faster speed of onset and greater efficacy than its individual ingredients or tacalcitol. After 4 weeks of therapy, the psoriasis area and severity index is reduced by approximately 70% and half of the patients have absent or very mild disease. Furthermore, more than half of the patients reach PASI-75 after 4 weeks of treatment. The calcipotriene/betamethasone dipropionate ointment is well tolerated with a safety profile similar to betamethasone dipropionate. It is associated with 50 and 75% fewer cutaneous adverse events than calcipotriene and tacalcitol, respectively.",
	pages = "791-797(7)",
	url = "http://www.ingentaconnect.com/content/ftd/edm/2006/00000001/00000006/art00008"
	doi = "doi:10.1586/17469872.1.6.791"
}